Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Emmaus Life Sciences Inc (EMMA)

Emmaus Life Sciences Inc (EMMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 912
  • Shares Outstanding, K 70,188
  • Annual Sales, $ 16,650 K
  • Annual Income, $ -6,450 K
  • EBIT $ -1 M
  • EBITDA $ 0 M
  • 60-Month Beta 10.83
  • Price/Sales 0.08
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.12
  • Most Recent Earnings $-0.03 on 11/14/25
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0130 unch
on 04/01/26
0.0153 -15.03%
on 03/27/26
-0.0010 (-7.14%)
since 02/27/26
3-Month
0.0122 +6.56%
on 01/05/26
0.0155 -16.13%
on 02/13/26
unch (unch)
since 12/31/25
52-Week
0.0080 +62.50%
on 10/20/25
0.0199 -34.67%
on 05/30/25
-0.0041 (-23.98%)
since 03/31/25

Most Recent Stories

More News
Emmaus Life Sciences Reports Annual Financial Results

Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition...

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Announces Strategic Transaction

Enters into North American License and Exclusive Distribution Agreement

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif. , Nov. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today...

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif. , Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Reports Management Changes

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Reports Q2 2023 Financial Results

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing...

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine...

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,...

EMMA : 0.0130 (-13.33%)
Emmaus Life Sciences Provides Interim Shipment Data

/PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle ell disease treatment, announced today preliminary results for the 3 months ended...

EMMA : 0.0130 (-13.33%)

Business Summary

Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States....

See More

Key Turning Points

3rd Resistance Point 0.0155
2nd Resistance Point 0.0150
1st Resistance Point 0.0140
Last Price 0.0130
1st Support Level 0.0125
2nd Support Level 0.0120
3rd Support Level 0.0110

See More

52-Week High 0.0199
Fibonacci 61.8% 0.0154
Fibonacci 50% 0.0139
Last Price 0.0130
Fibonacci 38.2% 0.0125
52-Week Low 0.0080

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.